These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 33665361)

  • 1. Tumor immune microenvironment-based classifications of bladder cancer for enhancing the response rate of immunotherapy.
    Meng J; Lu X; Zhou Y; Zhang M; Ge Q; Zhou J; Hao Z; Gao S; Yan F; Liang C
    Mol Ther Oncolytics; 2021 Mar; 20():410-421. PubMed ID: 33665361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy.
    Chen YP; Wang YQ; Lv JW; Li YQ; Chua MLK; Le QT; Lee N; Colevas AD; Seiwert T; Hayes DN; Riaz N; Vermorken JB; O'Sullivan B; He QM; Yang XJ; Tang LL; Mao YP; Sun Y; Liu N; Ma J
    Ann Oncol; 2019 Jan; 30(1):68-75. PubMed ID: 30407504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TIMEAS, a promising method for the stratification of testicular germ cell tumor patients with distinct immune microenvironment, clinical outcome and sensitivity to frontline therapies.
    Meng J; Gao J; Li X; Gao R; Lu X; Zhou J; Yan F; Wang H; Liu Y; Hao Z; Zhang X; Liang C
    Cell Oncol (Dordr); 2023 Jun; 46(3):745-759. PubMed ID: 36823338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and validation of tumour microenvironment-based immune molecular subgroups for gastric cancer: immunotherapeutic implications.
    Zhou YJ; Zhu GQ; Lu XF; Zheng KI; Wang QW; Chen JN; Zhang QW; Yan FR; Li XB
    Cancer Immunol Immunother; 2020 Jun; 69(6):1057-1069. PubMed ID: 32100076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune response drives outcomes in prostate cancer: implications for immunotherapy.
    Meng J; Zhou Y; Lu X; Bian Z; Chen Y; Zhou J; Zhang L; Hao Z; Zhang M; Liang C
    Mol Oncol; 2021 May; 15(5):1358-1375. PubMed ID: 33338321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment of a tumor immune microenvironment-based molecular classification system of breast cancer for immunotherapy.
    Zheng X; Li L; Yu C; Yang J; Zhao Y; Su C; Yu J; Xu M
    Aging (Albany NY); 2021 Nov; 13(21):24313-24338. PubMed ID: 34762599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Signature-Based Risk Stratification and Prediction of Immunotherapy Efficacy for Bladder Urothelial Carcinoma.
    Liang F; Xu Y; Chen Y; Zhong H; Wang Z; Nong T; Zhong J
    Front Mol Biosci; 2021; 8():673918. PubMed ID: 35004839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unraveling tumor microenvironment heterogeneity in malignant pleural mesothelioma identifies biologically distinct immune subtypes enabling prognosis determination.
    Yang K; Yang T; Yang T; Yuan Y; Li F
    Front Oncol; 2022; 12():995651. PubMed ID: 36237331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor Microenvironment Analysis Identified Subtypes Associated With the Prognosis and the Tumor Response to Immunotherapy in Bladder Cancer.
    Zhang H; Song J; Dong J; Liu Z; Lin L; Wang B; Ma Q; Ma L
    Front Genet; 2021; 12():551605. PubMed ID: 33732281
    [No Abstract]   [Full Text] [Related]  

  • 10. Identification of an Immune-Related Risk Signature Correlates With Immunophenotype and Predicts Anti-PD-L1 Efficacy of Urothelial Cancer.
    Li P; Hao S; Ye Y; Wei J; Tang Y; Tan L; Liao Z; Zhang M; Li J; Gui C; Xiao J; Huang Y; Chen X; Cao J; Luo J; Chen W
    Front Cell Dev Biol; 2021; 9():646982. PubMed ID: 33816497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Long Noncoding RNA Biomarkers With Clinical Immune Subtype and Prediction of Immunotherapy Response in Patients With Cancer.
    Yu Y; Zhang W; Li A; Chen Y; Ou Q; He Z; Zhang Y; Liu R; Yao H; Song E
    JAMA Netw Open; 2020 Apr; 3(4):e202149. PubMed ID: 32259264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MHC-II Signature Correlates With Anti-Tumor Immunity and Predicts anti-PD-L1 Response of Bladder Cancer.
    Yi R; Hong S; Zhang Y; Lin A; Ying H; Zou W; Wang Q; Wei T; Cheng Q; Zhu W; Luo P; Zhang J
    Front Cell Dev Biol; 2022; 10():757137. PubMed ID: 35223828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour microenvironment-based molecular profiling reveals ideal candidates for high-grade serous ovarian cancer immunotherapy.
    Lu X; Ji C; Jiang L; Zhu Y; Zhou Y; Meng J; Gao J; Lu T; Ye J; Yan F
    Cell Prolif; 2021 Mar; 54(3):e12979. PubMed ID: 33522069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and Validation of a Stromal EMT Related LncRNA Signature as a Potential Marker to Predict Bladder Cancer Outcome.
    Du Y; Wang B; Jiang X; Cao J; Yu J; Wang Y; Wang X; Liu H
    Front Oncol; 2021; 11():620674. PubMed ID: 33747932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel tumor gene expression signatures improve the overall survival prediction efficiency over tumor mutation burden and PD-L1 expression in bladder carcinoma with checkpoint blockade immunotherapy.
    Guo Y; Dai Y; Yin J; Song Y; Wang T; Zhang L; Lu YJ; Song D
    Am J Cancer Res; 2024; 14(9):4411-4428. PubMed ID: 39417183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of an immune classification for cervical cancer and integrative analysis of multiomics data.
    Lyu X; Li G; Qiao Q
    J Transl Med; 2021 May; 19(1):200. PubMed ID: 33971902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An RNA-sequencing-based transcriptome for a significantly prognostic novel driver signature identification in bladder urothelial carcinoma.
    Liu D; Zhou B; Liu R
    PeerJ; 2020; 8():e9422. PubMed ID: 32742772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-omics Perspective on the Tumor Microenvironment based on PD-L1 and CD8 T-Cell Infiltration in Urothelial Cancer.
    Chen S; Zhang N; Shao J; Wang T; Wang X
    J Cancer; 2019; 10(3):697-707. PubMed ID: 30719168
    [No Abstract]   [Full Text] [Related]  

  • 19. Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches.
    Song D; Powles T; Shi L; Zhang L; Ingersoll MA; Lu YJ
    J Pathol; 2019 Oct; 249(2):151-165. PubMed ID: 31102277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Landscape of the intratumroal microenvironment in bladder cancer:
    Bian Z; Chen J; Liu C; Ge Q; Zhang M; Meng J; Liang C
    Comput Struct Biotechnol J; 2023; 21():74-85. PubMed ID: 36514337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.